Non-specific chemical inhibition of the Fanconi anemia pathway sensitizes cancer cells to cisplatin

Molecular Cancer

Volumn 11, Issue , 2012, Pages

  Jacquemont, Céline ^a,b   Simon, Julian A ^b   D'Andrea, Alan D ^c   Taniguchi, Toshiyasu ^a,b  

^a HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Cisplatin; Drug resistance; Fanconi anemia; Homologous recombination; Small molecule

Indexed keywords

1 (2 METHOXY 1 NAPHTYL) 3 (3 PYRIDINYL) 2 PROPEN 1 ONE; 2 (2 PYRINYLMETHYLENE)QUINUCLIDIN 3 ONE; 2 NITRO 9,10 PHENANTHRENEDIONE 10 OXIME; ALSTERPAULLONE; BORTEZOMIB; CATHEPSIN B INHIBITOR; CHECKPOINT KINASE 1; CHELATING AGENT; CHLOROQUINE; CISPLATIN; CURCUMIN; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR; FANCONI ANEMIA GROUP D2 PROTEIN; FANCONI ANEMIA GROUP F PROTEIN; GELDANAMYCIN; HEAT SHOCK PROTEIN 90 INHIBITOR; LACTACYSTIN; PROTEASOME INHIBITOR; PROTEIN KINASE C INHIBITOR; PROTEIN SERINE THREONINE KINASE INHIBITOR; PUROMYCIN; PYRIDINE DERIVATIVE; QUINUCLIDINE DERIVATIVE; RAD51 PROTEIN; ROSCOVITINE; SB 218078; TANESPIMYCIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; WORTMANNIN;

ARTICLE; CANCER CELL CULTURE; CELL ASSAY; CELL SCREENING; CHEMOSENSITIZATION; CONTROLLED STUDY; DNA CROSS LINKING; DNA DAMAGE; DRUG POTENTIATION; DRUG SPECIFICITY; FANCONI ANEMIA; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE MICROSCOPY; IONIZING RADIATION; LYSOSOME; OVARY CANCER; PROTEIN PROCESSING; RECOMBINATION REPAIR; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; CISPLATIN; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; FANCONI ANEMIA COMPLEMENTATION GROUP D2 PROTEIN; FEMALE; HOMOLOGOUS RECOMBINATION; HUMANS; NEOPLASMS; OVARIAN NEOPLASMS; PROTEASOME INHIBITORS; RADIATION-SENSITIZING AGENTS; SIGNAL TRANSDUCTION; SMALL MOLECULE LIBRARIES;

EID: 84862161278     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-11-26     Document Type: Article

References (52)

1. McCabe KM, Olson SB, Moses RE. DNA interstrand crosslink repair in mammalian cells. J Cell Physiol 2009, 220:569-573. 10.1002/jcp.21811, 2760924, 19452447.
2. Rabik CA, Dolan ME. Molecular mechanisms of resistance and toxicity associated with platinating agents. Canc Treat Rev 2007, 33:9-23.
3. Dhillon KK, Swisher EM, Taniguchi T. Secondary mutations of BRCA1/2 and drug resistance. Canc Sci 2011, 102:663-669.
4. D'Andrea AD. Susceptibility pathways in Fanconi's anemia and breast cancer. N Engl J Med 2010, 362:1909-1919. 10.1056/NEJMra0809889, 3069698, 20484397.
5. Kee Y, D'Andrea AD. Expanded roles of the Fanconi anemia pathway in preserving genomic stability. Genes Dev 2010, 24:1680-1694. 10.1101/gad.1955310, 2922498, 20713514.
6. Stoepker C, Hain K, Schuster B, Hilhorst-Hofstee Y, Rooimans MA, Steltenpool J, Oostra AB, Eirich K, Korthof ET, Nieuwint AW, et al. SLX4, a coordinator of structure-specific endonucleases, is mutated in a new Fanconi anemia subtype. Nat Genet 2011, 43:138-141. 10.1038/ng.751, 21240277.
7. Kim Y, Lach FP, Desetty R, Hanenberg H, Auerbach AD, Smogorzewska A. Mutations of the SLX4 gene in Fanconi anemia. Nat Genet 2011, 43:142-146. 10.1038/ng.750, 3345287, 21240275.
8. Garcia-Higuera I, Taniguchi T, Ganesan S, Meyn MS, Timmers C, Hejna J, Grompe M, D'Andrea AD. Interaction of the Fanconi anemia proteins and BRCA1 in a common pathway. Mol Cell 2001, 7:249-262. 10.1016/S1097-2765(01)00173-3, 11239454.
9. Nijman SM, Huang TT, Dirac AM, Brummelkamp TR, Kerkhoven RM, D'Andrea AD, Bernards R. The deubiquitinating enzyme USP1 regulates the Fanconi anemia pathway. Mol Cell 2005, 17:331-339. 10.1016/j.molcel.2005.01.008, 15694335.
10. Jacquemont C, Taniguchi T. Disruption of the Fanconi anemia pathway in human cancer in the general population. Canc Biol Ther 2006, 5:1637-1639.
11. Taniguchi T, Tischkowitz M, Ameziane N, Hodgson SV, Mathew CG, Joenje H, Mok SC, D'Andrea AD. Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors. Nat Med 2003, 9:568-574. 10.1038/nm852, 12692539.
12. Sakai W, Swisher EM, Karlan BY, Agarwal MK, Higgins J, Friedman C, Villegas E, Jacquemont C, Farrugia DJ, Couch FJ, et al. Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature 2008, 451:1116-1120. 10.1038/nature06633, 2577037, 18264087.
13. Chirnomas D, Taniguchi T, de la Vega M, Vaidya AP, Vasserman M, Hartman AR, Kennedy R, Foster R, Mahoney J, Seiden MV, D'Andrea AD. Chemosensitization to cisplatin by inhibitors of the Fanconi anemia/BRCA pathway. Mol Cancer Ther 2006, 5:952-961. 10.1158/1535-7163.MCT-05-0493, 16648566.
14. Landais I, Hiddingh S, McCarroll M, Yang C, Sun A, Turker MS, Snyder JP, Hoatlin ME. Monoketone analogs of curcumin, a new class of Fanconi anemia pathway inhibitors. Mol Canc 2009, 8:133.
15. Landais I, Sobeck A, Stone S, LaChapelle A, Hoatlin ME. A novel cell-free screen identifies a potent inhibitor of the Fanconi anemia pathway. Int J Cancer 2009, 124:783-792. 10.1002/ijc.24039, 19048618.
16. Kee Y, Huang M, Chang S, Moreau L, Park E, Smith PG, D'Andrea AD. Inhibition of the Nedd8 system sensitizes cells to DNA Interstrand crosslinking agents. Mol Cancer Res 2012, 10:369-377. 10.1158/1541-7786.MCR-11-0497, 22219386.
17. Jana NR, Dikshit P, Goswami A, Nukina N. Inhibition of proteasomal function by curcumin induces apoptosis through mitochondrial pathway. J Biol Chem 2004, 279:11680-11685. 10.1074/jbc.M310369200, 14701837.
18. Jacquemont C, Taniguchi T. Proteasome function is required for DNA damage response and fanconi anemia pathway activation. Cancer Res 2007, 67:7395-7405. 10.1158/0008-5472.CAN-07-1015, 17671210.
19. Bence NF, Bennett EJ, Kopito RR. Application and Analysis of the GFP(u) Family of Ubiquitin-Proteasome System Reporters. Methods Enzymol 2005, 399:481-490.
20. Nakanishi K, Yang YG, Pierce AJ, Taniguchi T, Digweed M, D'Andrea AD, Wang ZQ, Jasin M. Human Fanconi anemia monoubiquitination pathway promotes homologous DNA repair. Proc Natl Acad Sci U S A 2005, 102:1110-1115. 10.1073/pnas.0407796102, 545844, 15650050.
21. Pierce AJ, Johnson RD, Thompson LH, Jasin M. XRCC3 promotes homology-directed repair of DNA damage in mammalian cells. Genes Dev 1999, 13:2633-2638. 10.1101/gad.13.20.2633, 317094, 10541549.
22. Taniguchi T, Garcia-Higuera I, Andreassen PR, Gregory RC, Grompe M, D'Andrea AD. S-phase-specific interaction of the Fanconi anemia protein, FANCD2, with BRCA1 and RAD51. Blood 2002, 100:2414-2420. 10.1182/blood-2002-01-0278, 12239151.
23. Moynahan ME, Chiu JW, Koller BH, Jasin M. Brca1 controls homology-directed DNA repair. Mol Cell 1999, 4:511-518. 10.1016/S1097-2765(00)80202-6, 10549283.
24. Shinohara A, Ogawa H, Ogawa T. Rad51 protein involved in repair and recombination in S. cerevisiae is a RecA-like protein. Cell 1992, 69:457-470. 10.1016/0092-8674(92)90447-K, 1581961.
25. Andrews PA, Albright KD. Mitochondrial defects in cis-diamminedichloroplatinum(II)-resistant human ovarian carcinoma cells. Cancer Res 1992, 52:1895-1901.
26. Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 2006, 58:621-681. 10.1124/pr.58.3.10, 16968952.
27. Murakawa Y, Sonoda E, Barber LJ, Zeng W, Yokomori K, Kimura H, Niimi A, Lehmann A, Zhao GY, Hochegger H, et al. Inhibitors of the proteasome suppress homologous DNA recombination in mammalian cells. Cancer Res 2007, 67:8536-8543. 10.1158/0008-5472.CAN-07-1166, 17875693.
28. Guervilly JH, Mace-Aime G, Rosselli F. Loss of CHK1 function impedes DNA damage-induced FANCD2 monoubiquitination but normalizes the abnormal G2 arrest in Fanconi anemia. Hum Mol Genet 2008, 17:679-689.
29. Wang X, Kennedy RD, Ray K, Stuckert P, Ellenberger T, D'Andrea AD. Chk1-mediated phosphorylation of FANCE is required for the Fanconi anemia/BRCA pathway. Mol Cell Biol 2007, 27:3098-3108. 10.1128/MCB.02357-06, 1899922, 17296736.
30. Andreassen PR, D'Andrea AD, Taniguchi T. ATR couples FANCD2 monoubiquitination to the DNA-damage response. Genes Dev 2004, 18:1958-1963. 10.1101/gad.1196104, 514175, 15314022.
31. Pichierri P, Rosselli F. The DNA crosslink-induced S-phase checkpoint depends on ATR-CHK1 and ATR-NBS1-FANCD2 pathways. EMBO J 2004, 23:1178-1187. 10.1038/sj.emboj.7600113, 380971, 14988723.
32. Sleeth KM, Sorensen CS, Issaeva N, Dziegielewski J, Bartek J, Helleday T. RPA mediates recombination repair during replication stress and is displaced from DNA by checkpoint signalling in human cells. J Mol Biol 2007, 373:38-47. 10.1016/j.jmb.2007.07.068, 17765923.
33. Oda T, Hayano T, Miyaso H, Takahashi N, Yamashita T. Hsp90 regulates the Fanconi anemia DNA damage response pathway. Blood 2007, 109:5016-5026. 10.1182/blood-2006-08-038638, 17327415.
34. Noguchi S. Predictive factors for response to docetaxel in human breast cancers. Canc Sci 2006, 97:813-820.
35. Arlander SJ, Eapen AK, Vroman BT, McDonald RJ, Toft DO, Karnitz LM. Hsp90 inhibition depletes Chk1 and sensitizes tumor cells to replication stress. J Biol Chem 2003, 278:52572-52577. 10.1074/jbc.M309054200, 14570880.
36. Maude SL, Enders GH. Cdk inhibition in human cells compromises chk1 function and activates a DNA damage response. Cancer Res 2005, 65:780-786.
37. Esashi F, Christ N, Gannon J, Liu Y, Hunt T, Jasin M, West SC. CDK-dependent phosphorylation of BRCA2 as a regulatory mechanism for recombinational repair. Nature 2005, 434:598-604. 10.1038/nature03404, 15800615.
38. Levesque AA, Kohn EA, Bresnick E, Eastman A. Distinct roles for p53 transactivation and repression in preventing UCN-01-mediated abrogation of DNA damage-induced arrest at S and G2 cell cycle checkpoints. Oncogene 2005, 24:3786-3796. 10.1038/sj.onc.1208451, 15782134.
39. Perez RP, Lewis LD, Beelen AP, Olszanski AJ, Johnston N, Rhodes CH, Beaulieu B, Ernstoff MS, Eastman A. Modulation of cell cycle progression in human tumors: a pharmacokinetic and tumor molecular pharmacodynamic study of cisplatin plus the Chk1 inhibitor UCN-01 (NSC 638850). Clin Cancer Res 2006, 12:7079-7085. 10.1158/1078-0432.CCR-06-0197, 17145831.
40. Wang Q, Fan S, Eastman A, Worland PJ, Sausville EA, O'Connor PM. UCN-01: a potent abrogator of G2 checkpoint function in cancer cells with disrupted p53. J Natl Canc Inst 1996, 88:956-965.
41. Ma CX, Janetka JW, Piwnica-Worms H. Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics. Trends Mol Med 2011, 17:88-96. 10.1016/j.molmed.2010.10.009, 21087899.
42. Chen CC, Kennedy RD, Sidi S, Look AT, D'Andrea AD. CHK1 inhibition as a strategy for targeting fanconi anemia (FA) DNA repair pathway deficient tumors. Mol Canc 2009, 8:24.
43. Tse AN, Sheikh TN, Alan H, Chou TC, Schwartz GK. 90-kDa heat shock protein inhibition abrogates the topoisomerase I poison-induced G2/M checkpoint in p53-null tumor cells by depleting Chk1 and Wee1. Mol Pharmacol 2009, 75:124-133. 10.1124/mol.108.050807, 2685054, 18820127.
44. McCollum AK, Lukasiewicz KB, Teneyck CJ, Lingle WL, Toft DO, Erlichman C. Cisplatin abrogates the geldanamycin-induced heat shock response. Mol Cancer Ther 2008, 7:3256-3264. 10.1158/1535-7163.MCT-08-0157, 2572571, 18852129.
45. Hubbard J, Erlichman C, Toft DO, Qin R, Stensgard BA, Felten S, Ten Eyck C, Batzel G, Ivy SP, Haluska P. Phase I study of 17-allylamino-17 demethoxygeldanamycin, gemcitabine and/or cisplatin in patients with refractory solid tumors. Investig New Drugs 2011, 29:473-480.
46. Kling J. New twists on proteasome inhibitors. Nat Biotechnol 2010, 28:1236-1238. 10.1038/nbt.1727, 21139600.
47. Solomon VR, Lee H. Chloroquine and its analogs: a new promise of an old drug for effective and safe cancer therapies. Eur J Pharmacol 2009, 625:220-233. 10.1016/j.ejphar.2009.06.063, 19836374.
48. Kennedy RD, Chen CC, Stuckert P, Archila EM, De la Vega MA, Moreau LA, Shimamura A, D'Andrea AD. Fanconi anemia pathway-deficient tumor cells are hypersensitive to inhibition of ataxia telangiectasia mutated. J Clin Invest 2007, 117:1440-1449. 10.1172/JCI31245, 1847538, 17431503.
49. Weinstock DM, Nakanishi K, Helgadottir HR, Jasin M. Assaying double-strand break repair pathway choice in mammalian cells using a targeted endonuclease or the RAG recombinase. Methods Enzymol 2006, 409:524-540.
50. Richardson C, Moynahan ME, Jasin M. Double-strand break repair by interchromosomal recombination: suppression of chromosomal translocations. Genes Dev 1998, 12:3831-3842. 10.1101/gad.12.24.3831, 317271, 9869637.
51. Elliott PJ, Soucy TA, Pien CS, Adams J, Lightcap ES. Assays for proteasome inhibition. Meth Mol Med 2003, 85:163-172.
52. Tsai CM, Gazdar AF, Venzon DJ, Steinberg SM, Dedrick RL, Mulshine JL, Kramer BS. Lack of in vitro synergy between etoposide and cis-diamminedichloroplatinum(II). Cancer Res 1989, 49:2390-2397.